| Followers | 33 |
| Posts | 7944 |
| Boards Moderated | 1 |
| Alias Born | 04/28/2013 |
Monday, January 10, 2022 5:52:37 PM
My worry is O catalysts In The pipeline. Zero revenue forecasts. No word on Canada or USA BLA submission
While BB and covaxin are doing gr8, we. On the other hand are not
While BB and covaxin are doing gr8, we. On the other hand are not
Recent OCGN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 01:26:46 AM
- Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease • GlobeNewswire Inc. • 04/01/2026 11:02:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 04:02:11 PM
- Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration • GlobeNewswire Inc. • 03/24/2026 11:45:00 AM
- Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy • GlobeNewswire Inc. • 03/23/2026 11:02:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 12:00:18 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 02:27:38 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/04/2026 05:23:26 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/04/2026 04:38:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 04:12:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 04:07:26 PM
- Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 03/04/2026 01:15:00 PM
- Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa • GlobeNewswire Inc. • 03/02/2026 12:02:00 PM
- Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/18/2026 12:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:59:25 PM
- Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer • GlobeNewswire Inc. • 02/09/2026 12:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2026 01:12:02 PM
- Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock • GlobeNewswire Inc. • 01/23/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/21/2026 10:29:15 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/21/2026 10:27:56 PM
- Ocugen shares slide after company prices $22.5 million equity raise • IH Market News • 01/21/2026 03:35:56 PM
- Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock • GlobeNewswire Inc. • 01/21/2026 01:32:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 01:31:02 PM
- Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration • GlobeNewswire Inc. • 01/15/2026 01:15:00 PM
- Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data • GlobeNewswire Inc. • 01/13/2026 12:00:00 PM
